Education
About Us
Working with TipRanks
Follow Us
Omniab, Inc. (OABI)
:OABI
OABI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.22 - $4.87
Previous CloseN/A
Volume80.31K
Average Volume (3M)466.79K
Market Cap
$197.55M
Enterprise Value$164.87M
Total Cash (Recent Filing)$41.62M
Total Debt (Recent Filing)$21.78M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 18, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding122,701,294
10 Day Avg. Volume414,635
30 Day Avg. Volume466,791
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue7.16
Enterprise Value/Gross Profit9.10
Enterprise Value/Ebitda-3.10
Forecast
1Y Price Target
$7.50Price Target Upside365.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Business ModelOABI is viewed as a differentiated antibody therapeutics animal platform provider, enabling market-leading partner program growth and a highly scalable business model.
R&D PipelineOmniAb's partnered pipeline shows significant progress with new clinical trials and FDA Fast Track Designation for various programs, indicating strong potential for growth.
Technology And InnovationThe launch of OmniAb's data-centered, AI/ML-driven tech xPloration product could provide new avenues for revenue generation as partner adoption begins.
Bears Say
Financial PerformanceOmniAb reported revenue of $3.9 million compared to an estimate of $5.4 million, indicating a shortfall in expected financial performance.
Revenue ChallengesQ2 revenues of $3.9M included OABI's first xPloration revenues, but overall revenues declined by 49% year over year, highlighting a significant drop in sales.
Revenue GuidanceManagement reaffirmed FY25 revenues guidance with a potential downside, citing challenges in predicting drug discovery partner revenues.
OmniAb News
OABI FAQ
What was Omniab, Inc.’s price range in the past 12 months?
Omniab, Inc. lowest stock price was $1.22 and its highest was $4.87 in the past 12 months.
What is Omniab, Inc.’s market cap?
Omniab, Inc.’s market cap is $197.55M.
When is Omniab, Inc.’s upcoming earnings report date?
Omniab, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 61 days.
How were Omniab, Inc.’s earnings last quarter?
Omniab, Inc. released its earnings results on Aug 06, 2025. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.149 by -$0.001.
Is Omniab, Inc. overvalued?
According to Wall Street analysts Omniab, Inc.’s price is currently Undervalued.
Does Omniab, Inc. pay dividends?
Omniab, Inc. does not currently pay dividends.
What is Omniab, Inc.’s EPS estimate?
Omniab, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Omniab, Inc. have?
Omniab, Inc. has 122,701,294 shares outstanding.
What happened to Omniab, Inc.’s price movement after its last earnings report?
Omniab, Inc. reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.149. Following the earnings report the stock price went down -2.591%.
Which hedge fund is a major shareholder of Omniab, Inc.?
Currently, no hedge funds are holding shares in OABI
OmniAb Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (365.84% Upside)
$7.50 (365.84% Upside)
Hedge Fund Trend
Decreased
By 108.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.4%
Last 30 Days ▼ 10.9%
Last 30 Days ▼ 10.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.69%
12-Months-Change
Fundamentals
Return on Equity
-22.84%
Trailing 12-Months
Asset Growth
-12.33%
Trailing 12-Months
Company Description
Omniab, Inc.
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
OABI Company Deck
OABI Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Despite a notable decrease in quarterly revenue and increased net loss, OmniAb showed strong momentum in partnerships and active programs, with high potential future milestones and successful technology launches, suggesting a positive outlook.View all OABI earnings summariesOABI Stock 12 Month Forecast
Average Price Target
$7.50
▲(365.84% Upside)
Technical Analysis
Ownership Overview
6.14% Insiders
18.83% Mutual Funds
19.14% Other Institutional Investors
47.64% Public Companies and
Individual Investors